Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Cardiac lipoma

Cardiac lipoma is a benign neoplasm composed of mature adipose tissue, generally surrounded by a thin fibrous capsule, which may develop within the heart or pericardium. Growth may project toward a chamber, remain within the myocardium, or be predominantly epicardial and intrapericardial. This anatomical distribution explains a wide range of presentations: small incidental nodules, obstructive lesions and bulky masses capable of compressing the heart or altering its electrical function. The fatty component can be identified with high reliability by CT and MRI, but recognizing fat is only part of the assessment: the lesion's organization, attachment and relationships with adjacent structures must also be established.

A true lipoma must be distinguished from lipomatous hypertrophy of the interatrial septum, a nonencapsulated fat accumulation with a characteristic distribution, and from the normal presence of epicardial fat. Grouping these conditions under the same name distorts both epidemiological estimates and treatment indications. Diffuse adipose tissue expansion and a well-defined neoplastic mass may share the appearance of fat on imaging, but have different biological significance and clinical consequences.
Lipoma represents a small proportion of primary cardiac tumors. The percentages reported in historical series are heterogeneous and sometimes include other adipose lesions. The review by Shu and colleagues collected 255 patients reported in the literature, documenting intracavitary, myocardial and pericardial locations. These are selected cases, often published because they were symptomatic or unusual, rather than a population from which to calculate the probability that every incidentally discovered lipoma will become dangerous. Diagnosis is possible at any age, although it is reported more often in adults.

Etiology, pathogenesis and pathological anatomy

The etiology remains largely unknown. The lesion arises from local adipocyte proliferation, but the mechanisms governing its development at a particular cardiac site have not been established. Molecular knowledge derived from extracardiac lipomas, which may contain rearrangements of genes involved in growth regulation, cannot automatically be extrapolated to all cardiac lesions. Pathological series incorporating cytogenetic evaluation also demonstrate the importance of separating adipose neoplasms, nonneoplastic accumulations and reparative phenomena before proposing a unified explanation.

Obesity and abundant epicardial fat are not diagnostic criteria for lipoma and do not necessarily explain its origin. No routine family genetic screening program is recognized for an isolated cardiac lipoma. The presence of other lipomas or syndromic features may warrant a broader assessment prompted by the overall presentation, without assigning an unproven inherited origin to the individual mass. Likewise, the appearance of an adipose lesion does not imply a systemic disorder of lipid metabolism.

The conventional form consists of relatively uniform mature adipocytes with large lipid vacuoles and peripheral nuclei, separated by thin connective tissue septa and small vessels. The capsule delineates the mass and, when present and accessible, facilitates separation from surrounding tissue. Histology assesses cellular uniformity, stromal components and any atypical areas. Fat necrosis, degenerative changes and variable amounts of fibrous tissue may make a specimen less homogeneous without, on their own, proving malignancy.
The diagnosis of liposarcoma requires different features and, in uncertain cases, specialist pathological characterization. Immunohistochemical or molecular tests are selected according to the specific concern; they are not an automatic step for every small lipoma with conventional morphology.

The site of origin determines the growth pattern. A subendocardial lipoma may project into a chamber and have a broad base or, less commonly, a narrower attachment. An intramyocardial lesion expands between the fibers and may make it difficult to define a plane of separation. Epicardial or pericardial lesions may reach considerable dimensions before causing obvious symptoms. Forms that infiltrate the myocardium have also been described, in which cellular benignity coexists with locally problematic growth.

In this context, the word infiltrating describes an anatomical relationship and does not automatically establish the presence of a sarcoma. Conventional lipoma has no documented normal progression to a malignant neoplasm; nevertheless, a mass that develops atypical solid components, rapid changes or discordant features requires renewed diagnostic assessment. The challenge is to distinguish a lesion initially classified incompletely from benign growth with mechanical consequences, without equating size alone with biological aggressiveness.

Pathophysiology: obstruction, compression and arrhythmogenic substrate

An intracavitary mass may reduce the available volume or obstruct blood passage. The significance of obstruction depends on proximity to valves and outflow tracts, the ratio of tumor size to chamber size and flow conditions. Protrusion into the ventricular outflow tract may increase the work required for ejection; interference with inflow may limit filling and reduce cardiac output. The effect must be demonstrated by dynamic imaging and Doppler because a large mass in a favorable location may have fewer consequences than a smaller one in a critical position.

Extrinsic compression is particularly relevant for epicardial and pericardial lesions. Expansion may deform a chamber, restrict filling or interfere with major vessels and coronary structures. Fat surrounding a coronary artery, however, does not amount to stenosis: narrowing or a consistent functional effect must be documented before attributing ischemic pain to the mass. In some extensive lesions, adjacent myocardium may become thinner and its motion may change, adding a structural problem to mere space occupation.

The arrhythmic risk mainly concerns intramyocardial lipomas or those related to the conduction system. Interposed adipose and fibrous tissue can disrupt the continuity of muscle bundles and promote heterogeneous conduction; extrasystoles, tachycardias, bradycardias or blocks may occur according to location. A preserved ejection fraction does not exclude this mechanism. Even after resection, a previously altered myocardial substrate may still require electrophysiological attention.

Embolization is much less characteristic than with myxoma or fibroelastoma, as most lipomas are compact, covered and poorly mobile. However, a pedunculated lesion exposed to blood flow or an associated thrombotic component may introduce a specific risk. Decisions must be based on observed anatomy and clinical events, without applying estimates derived from friable tumors to all lipomas. Adipose tissue in itself is not an indication for anticoagulation.

Clinical manifestations, history and physical examination

Many lipomas are identified during investigations performed for other reasons. In symptomatic patients, dyspnea, reduced exercise tolerance, chest tightness, palpitations and syncope are sought. The time course of symptoms helps distinguish a recent complaint from a pre-existing condition and compare it with the documented evolution of the mass. Common symptoms in someone with obesity, coronary artery disease or valvular disease must not be attributed to the lipoma simply because it was discovered at the same time.
Attribution becomes more convincing when a demonstrable mechanism exists: flow obstruction, compression, chamber deformation or an arrhythmia consistent with the location. In the absence of such correspondence, it may be necessary to treat or further investigate a concomitant heart disease before proposing removal as a solution to symptoms.

Palpitations require documentation of onset, duration, regularity and associated symptoms. Sudden loss of consciousness, sustained tachycardia or resuscitated cardiac arrest calls for urgent rhythm assessment even if the mass appears benign on imaging. Dyspnea, orthopnea and edema suggest hemodynamic effects, while exertional pain also requires consideration of common coronary artery disease. A history of previous resection is particularly important for large pericardial masses because a residual lesion growing over time may be plausible.

Previous documentation should be reviewed directly whenever possible, checking the site, measurement planes and availability of fat-specific sequences. A difference of a few millimeters between different modalities may reflect technical variation; reproducible enlargement or a new wall abnormality carries greater significance. The history includes known heart disease, procedures, arrhythmias, antithrombotic therapy and conditions affecting surgical risk. Normal blood tests or the absence of lipid abnormalities do not exclude the lesion.

The physical examination assesses rhythm, blood pressure, perfusion and signs of congestion. A murmur may occur when there is obstruction or valve interference, whereas a pericardial lipoma may cause compression without a characteristic sound. In patients with arrhythmia, the pulse findings help assess urgency, but an electrocardiographic recording is needed to establish its nature. A normal examination is common with incidental findings and does not contradict the presence of a mass. The clinical examination mainly determines whether the patient is stable and which functional consequences require further investigation.

Diagnostic investigations and characterization of adipose tissue

Transthoracic echocardiography localizes the lesion, assesses its attachment and describes its relationship to chambers and valves. Echogenicity may be high in intracavitary lesions, while pericardial masses can have different appearances; echocardiography alone does not always identify the fatty composition. Doppler quantifies any gradient or regurgitation and ventricular assessment documents contractility and filling. When an apparently external mass deforms the heart, compression must be distinguished from an intramural origin.

Transesophageal echocardiography is selected for particular questions, such as a poorly defined atrial attachment or its relationship with a valve. Adequate transthoracic imaging of a ventricular lesion and already conclusive MRI findings may make it unnecessary. For extensive pericardial masses, CT and MRI often provide a more complete map of the entire volume. The diagnostic pathway benefits from complementary modalities rather than their systematic use in every patient.

CT identifies macroscopic fat through markedly negative attenuation values, often close to those of subcutaneous adipose tissue. A conventional lipoma is well defined, predominantly homogeneous and lacks a substantial solid contrast-enhancing component. Thin septa or a capsule may be visible. Density measurements must avoid edges, vessels and partial-volume areas, which may simulate a mixed composition.
CT also defines relationships with coronary arteries, pericardium and mediastinum and may clarify whether a lesion is genuinely cardiac. Electrocardiographic gating is useful when motion impairs the examination, whereas the choice of contrast depends on the need to assess vascularization and vascular relationships. An already diagnostic chest CT showing a small fatty lesion may avoid additional examinations that answer no new question.

Cardiac MRI provides particularly effective tissue characterization. A lipoma shows a signal similar to fat across sequences, generally high on T1-weighted images, and a marked signal decrease on fat-suppressed acquisitions. Agreement between the baseline signal and the response to suppression is more informative than simply detecting a bright area. Cine sequences define motion, mobility and chamber deformation; post-contrast images look for nonadipose components and abnormalities of the adjacent myocardium.

The absence of significant enhancement within the bulk of the mass is consistent with a simple lipoma, whereas nonadipose nodular portions, irregular septa or discordant findings need further investigation. Size alone does not separate lipoma from liposarcoma. In the imaging series of Shu and colleagues, involving twelve patients, CT and MRI informed not only diagnosis but also treatment decisions, showing obstruction, narrow attachments or myocardial extension. The series illustrates the value of anatomical mapping without turning the observed accuracy into a universal guarantee.

The differential diagnosis first considers other adipose lesions. Lipomatous hypertrophy has a typical septal distribution and spares the fossa ovalis; normal epicardial fat follows surfaces and grooves without forming an encapsulated mass. Fatty metaplasia in a myocardial scar is interpreted in conjunction with the ischemic history, wall abnormalities and fibrosis. Fat in the right ventricle alone does not establish arrhythmogenic cardiomyopathy, which requires a separate assessment. A mass containing fat, solid tissues and other components instead requires consideration of different entities according to location and age.

Suspicion of liposarcoma rises when atypical tissue components, heterogeneous architecture, solid nodules or extension poorly compatible with conventional lipoma predominate. Some well-differentiated forms nevertheless retain a high proportion of fat, while a benign lipoma can be large or infiltrating. For this reason, decisions about sampling require joint imaging and pathology assessment. An indeterminate finding should be described as such, without using the word lipoma to provide unsupported reassurance.

Comparison with thrombi and other tumors mainly enters the diagnostic pathway before the fatty composition has been established. Clinical context and characterization by CT or MRI reduce this uncertainty. There are no specific blood markers or clinical scoring criteria for cardiac lipoma. Histology confirms the diagnosis in operated patients; when the imaging appearance is typical and conservative management is chosen, a concordant noninvasive diagnosis may be sufficient. Biopsy is reserved for situations in which its result would genuinely change management and the sampling risk is acceptable.

Further investigations and assessment of clinical significance

After fat has been identified, it is necessary to establish whether the mass is functionally significant. Any obstruction, compression or contractile abnormalities are quantified, and valves, adjacent coronary arteries and the conduction system are evaluated in relation to the site. Ambulatory electrocardiographic monitoring is indicated when palpitations, syncope or an intramyocardial location raise concern about arrhythmias. The duration of monitoring should match the frequency of symptoms, while electrophysiological testing follows specific indications rather than the mere presence of fatty tissue.

Surgical planning requires knowing whether a plane of separation exists, how much wall is involved and which structures could be damaged during removal. A superficial encapsulated mass and an extensive intramyocardial lesion do not carry the same technical risk. Comparison with earlier studies helps distinguish stability from growth and identify progressive effects such as wall thinning or deformation. When imaging is uncertain, review at an experienced center may be more useful than repeating investigations without a targeted question.

A typical fatty lesion does not warrant generalized oncological staging. A search for extracardiac sites or a primary neoplasm is considered when the presentation suggests an alternative diagnosis. PET is not a standard step for a simple lipoma, and any metabolic data do not replace anatomical characterization. General and coronary preoperative evaluations are instead chosen according to the patient and planned procedure as part of an overall risk assessment.

Treatment, prognosis and surveillance

Resection is generally considered when a lipoma causes obstruction, significant compression, cardiac dysfunction or plausibly related arrhythmias, or when the diagnosis remains uncertain. Documented growth with anatomical consequences may also support intervention. Indications derive from clinical experience and case series: there is no universal size threshold or validated algorithm requiring removal of every asymptomatic lipoma. Anatomy and individual history matter more than a single measurement.

A surveillance strategy is reasonable for well-characterized lesions without hemodynamic or arrhythmic effects or signs of concerning evolution, particularly when surgery entails substantial risk. The plan should specify how the lesion will be measured and what changes would prompt reassessment of the indication. Echocardiography and MRI can be combined according to location; repeat CT is weighed against radiation exposure. The frequency and duration of monitoring remain individualized because the natural history has been incompletely documented.

Surgery aims to remove the mass while preserving myocardium, valves, coronary arteries and conduction tissue. A superficial encapsulated lipoma may allow limited excision; intracavitary or deep lesions may require cardiopulmonary bypass and wall reconstruction. In infiltrating forms, the goal of complete removal must be balanced against the functional damage it could cause. A justified partial resection or conservative management may be preferable when complete excision would compromise essential structures.
Removed tissue must undergo histological examination. In exceptional cases of extensive unresectable disease with severe impairment, advanced options, including transplantation in selected patients, have been discussed, but these experiences do not define the usual care pathway for cardiac lipoma.

Arrhythmia treatment depends on the type of disorder and the clinical risk. Removing the mass may eliminate a triggering factor, but does not guarantee disappearance of every electrical substrate; drugs, ablation or devices are considered according to specific indications. Congestive symptoms may require supportive treatment while a definitive decision is pending. Anticoagulants and antiplatelet agents have a role when there is another indication or a documented thrombotic component, not as treatment for lipomatous tissue. No established drug therapy can induce regression of a true cardiac lipoma.

Weight management and control of cardiovascular risk factors remain valuable for general health and procedural risk, but are not equivalent to a proven cure for an encapsulated mass. Radiotherapy and chemotherapy are not part of the usual treatment of conventional lipoma. In an asymptomatic patient, the benefit of observation lies in avoiding unjustified surgical risk while retaining the ability to detect clinically important changes.

Prognosis is generally favorable for circumscribed lesions and after effective excision. The main limitations arise from intramyocardial location, infiltrating extent, arrhythmias and existing wall damage. Recurrences are reported but uncommon in published series; risk increases particularly when unresectable tissue remains. The available series are too selected to provide a single rate valid for every patient.
After surgery, follow-up documents the residual anatomy and function, allowing subsequent studies to be interpreted. For nonoperated lesions, long-term stability supports conservative management, whereas new symptoms, reproducible growth or tissue changes call for renewed assessment.

Local, arrhythmic and procedural complications

Complications depend primarily on the relationship with cardiac tissue: heart failure due to obstruction or compression, valve dysfunction, impaired filling and regional wall abnormalities. Involvement of conduction pathways may cause blocks, while a ventricular substrate may sustain life-threatening tachycardias. Ischemia from coronary compression, embolization and sudden death have been described in particular presentations; their rarity means that risk must not be generalized to all incidentally found fatty masses.

Surgery for deep lesions may be complicated by bleeding, myocardial injury, conduction disturbances or damage to an adjacent valve or vascular structure. Residual tissue may continue to grow and requires surveillance consistent with its location, while new imaging findings after excision should be compared with the operative report and histology. The initial distinction between a separable mass and a lesion diffusely involving the myocardium is thus crucial for preventing late complications and setting realistic expectations of treatment outcomes.

References
  1. Shu S et al. From pathogenesis to treatment, a systemic review of cardiac lipoma. Journal of Cardiothoracic Surgery. 2021;16:1.
  2. Shu S et al. The value of multimodality imaging in diagnosis and treatment of cardiac lipoma. BMC Medical Imaging. 2021;21:71.
  3. Bois MC et al. Benign lipomatous masses of the heart: a comprehensive series of 47 cases with cytogenetic evaluation. Human Pathology. 2014;45(9):1859-1865.
  4. Pruente R et al. Fatty lesions in and around the heart: a pictorial review. British Journal of Radiology. 2015;88(1051):20150157.
  5. Tyebally S et al. Cardiac Tumors: JACC CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2020;2(2):293-311.
  6. Basso C et al. Cardiac masses and tumours. Heart. 2016;102(15):1230-1245.
  7. Angeli F et al. Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2024;6(6):847-862.
  8. Mousavi N et al. Assessment of Cardiac Masses by Cardiac Magnetic Resonance Imaging: Histological Correlation and Clinical Outcomes. Journal of the American Heart Association. 2019;8(1):e007829.
  9. Shenoy C et al. Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study. European Heart Journal. 2022;43(1):71-80.
  10. Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229-4361.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.